Study Comparing Standard Dose and High-dose Imatinib Mesylate in Patients With Chronic Phase Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML)

NCT00171899 · clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
80
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Novartis Pharmaceuticals